MedTrace Logo

Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy

NCT00085761 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2008-03-06

No results posted yet for this study

Summary

The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.

Conditions

  • HIV Infections
  • Peripheral Nervous System Diseases
  • Pain

Interventions

DRUG

Capsaicin Dermal Patch

Sponsors & Collaborators

  • NeurogesX

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00085761 on ClinicalTrials.gov